Literature DB >> 9316826

Intestinal effects of isoprostanes: evidence for the involvement of prostanoid EP and TP receptors.

J L Elmhurst1, P A Betti, P K Rangachari.   

Abstract

The isoprostanes, which differ from prostaglandins by the cis orientation of their side chains, are believed to exert their biological effects on either a prostanoid TP receptor or a "unique" isoprostane receptor. Preliminary experiments suggested that canine colonic epithelium possessed no prostanoid TP receptor activity, in contrast to the muscularis mucosae, which responds well to the selective prostanoid TP receptor agonist U46619. To define the receptors involved, the in vitro responses of the epithelium and muscularis mucosae from the canine proximal colon to both 8-iso-PGE2 and 8-iso-PGF2alpha were compared. The epithelium responded to 8-iso-PGE2 but not to 8-iso-PGF2alpha. Under basal conditions, 8-iso-PGE2 produced concentration-dependent increases in short circuit current (pEC50 = 6.4 +/- 0.1) that were not antagonized by the selective prostanoid TP receptor antagonist SQ29548 (10(-6) M). Cross-desensitization experiments suggested that the stimulant effects involved a prostanoid EP receptor. Desensitization of the epithelium to PGE2 resulted in unexpected decreases in short circuit current in response to 8-iso-PGE2 (10(-6) M). This effect was mimicked by the selective prostanoid TP receptor agonist U46619 (10(-5) M), and antagonized by three structurally different prostanoid TP receptor antagonists: L670596 (10(-6) M), SQ29548 (10(-6) M) and GR32191 (10(-6) M). 8-Iso-PGE2, 8-iso-PGF2alpha and U46619 caused concentration-dependent increases in the force of contraction of the muscularis mucosae strips. These responses were antagonized by selective prostanoid TP receptor antagonists, arguing for the involvement of prostanoid TP receptors. Thus, the effects of isoprostanes on the canine colon involve both prostanoid TP and EP receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9316826

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles.

Authors:  L J Janssen; M Premji; S Netherton; J Coruzzi; H Lu-Chao; P G Cox
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine.

Authors:  H Li; J A Lawson; M Reilly; M Adiyaman; S W Hwang; J Rokach; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

3.  Characterization of prostanoid receptors mediating actions of the isoprostanes, 8-iso-PGE(2) and 8-iso-PGF(2alpha), in some isolated smooth muscle preparations.

Authors:  W Sametz; S Hennerbichler; S Glaser; R Wintersteiger; H Juan
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

4.  Effects of some isoprostanes on the human umbilical artery in vitro.

Authors:  L Oliveira; N A Stallwood; D J Crankshaw
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

5.  Regulation of [³H]d-aspartate release by the 5-F(2t)-isoprostane and its 5-epimer in isolated bovine retina.

Authors:  Jamal Jamil; Ashley Wright; Na'cara Harrison; Edem Kegey; Arnecia Faye Flowers; Namonique Jarell Flyod; Casey Kotera; Alexandre Guy; Jean-Marie Galano; Thierry Durand; Ya Fatou Njie-Mbye; Sunny E Ohia; Catherine A Opere
Journal:  Neurochem Res       Date:  2011-11-13       Impact factor: 3.996

Review 6.  The isoprostanes--25 years later.

Authors:  Ginger L Milne; Qi Dai; L Jackson Roberts
Journal:  Biochim Biophys Acta       Date:  2014-10-30

Review 7.  Role of oxidized lipids in pulmonary arterial hypertension.

Authors:  Salil Sharma; Grégoire Ruffenach; Soban Umar; Negar Motayagheni; Srinivasa T Reddy; Mansoureh Eghbali
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

8.  Brain-penetrant tetrahydronaphthalene thromboxane A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimer's disease.

Authors:  James H Soper; Shimpei Sugiyama; Katie Herbst-Robinson; Michael J James; Xiaozhao Wang; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee; Carlo Ballatore; Kurt R Brunden
Journal:  ACS Chem Neurosci       Date:  2012-07-27       Impact factor: 4.418

Review 9.  Isoprostanes: more than just mere markers.

Authors:  D J Crankshaw; P K Rangachari
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

Review 10.  Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation.

Authors:  Jochen Bauer; Anne Ripperger; Stefan Frantz; Süleyman Ergün; Edzard Schwedhelm; Ralf A Benndorf
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.